Roche to drive therapies to treat breast and lung cancer

06 July 2021 | Tuesday | News

Roche drives the evolution of innovative therapies that change the course of breast and lung cancer Roche molecule demonstrated an increase in survival of patients with lung cancer and triple negative breast cancer.
Image Source : Public Domain

Image Source : Public Domain

According to Globocan, in 2020 the global burden of cancer increased to 19.3 million new cases and 10 million deaths[1]. Worldwide, the most common type of cancer in men was lung cancer with 1.4 million new cases and in women it was breast cancer with 2.2 million new cases.[2]

Lung cancer is one of the leading causes of death from cancer in Mexico and worldwide, registering in 2020 6,733 deaths from this cause[3].

Dr. Isabela Rivas,medical lead for lung cancer at Roche Mexico, explained that there are two types of lung cancer, non-small cell and small cell. "For the latter there had been no progression for more than 20 years, as it is an aggressive disease with global survivals of no more than 10 months. Thanks to research and development, immunotherapy exists today, which helps the body fight tumor cells offering a global survival of just over a year," he said.

On the other hand, breast cancer in Mexico represents the leading cause of death from cancer in women[4]. In 2020, it represented almost 30 thousand new cases and caused the death of almost 8 thousand women in the country[5].

According to Dr. Angélica Ávila, medical lead for breast cancer at Roche Mexico: "Triple negative breast cancer is responsible for 15%-20% of breast cancer cases[6]. "Fortunately, there are immune checkpoint inhibitor drugs today. By inhibiting immune checkpoint proteins such as PD-L1 or PD-1, these drugs improve immune cells to find and attack cancer cells," emphasized Dr. Avila.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in